» Articles » PMID: 16287967

Anxiolytic- and Antidepressant-like Profiles of the Galanin-3 Receptor (Gal3) Antagonists SNAP 37889 and SNAP 398299

Abstract

The neuropeptide galanin mediates its effects through the receptor subtypes Gal(1), Gal(2), and Gal(3) and has been implicated in anxiety- and depression-related behaviors. Nevertheless, the receptor subtypes relevant to these behaviors are not known because of the lack of available galanin-selective ligands. In this article, we use behavioral, neurochemical, and electrophysiological approaches to investigate the anxiolytic- and antidepressant-like effects of two potent small-molecule, Gal(3)-selective antagonists, SNAP 37889 and the more soluble analog SNAP 398299. Acute administration of SNAP 37889 or SNAP 398299 enhanced rat social interaction. Furthermore, acute SNAP 37889 was also shown to reduce guinea pig vocalizations after maternal separation, to attenuate stress-induced hyperthermia in mice, to increase punished drinking in rats, and to decrease immobility and increase swimming time during forced swim tests with rats. Moreover, SNAP 37889 increased the social interaction time after 14 days of treatment and maintained its antidepressant effects during forced swim tests with rats after 21 days of treatment. In microdialysis studies, SNAP 37889 partially antagonized the galanin-evoked reduction in hippocampal serotonin (5-hydroxytryptamine, 5-HT), as did the 5-HT(1A) receptor antagonist WAY100635. Their combination produced a complete reversal of the effect of galanin. SNAP 398299 partially reversed the galanin-evoked inhibition of dorsal raphe cell firing and galanin-evoked hyperpolarizing currents. These results indicate that Gal(3)-selective antagonists produce anxiolytic- and antidepressant-like effects, possibly by attenuating the inhibitory influence of galanin on 5-HT transmission at the level of the dorsal raphe nucleus.

Citing Articles

Galanin receptor 3 - A new pharmacological target in retina degeneration.

Ortega J, Parmar T, Jastrzebska B Pharmacol Res. 2023; 188:106675.

PMID: 36693600 PMC: 9918719. DOI: 10.1016/j.phrs.2023.106675.


Spexin and Galanin in Metabolic Functions and Social Behaviors With a Focus on Non-Mammalian Vertebrates.

Mohd Zahir I, Ogawa S, Dominic N, Soga T, Parhar I Front Endocrinol (Lausanne). 2022; 13:882772.

PMID: 35692389 PMC: 9174643. DOI: 10.3389/fendo.2022.882772.


Dysfunctional Heteroreceptor Complexes as Novel Targets for the Treatment of Major Depressive and Anxiety Disorders.

Perez de la Mora M, Borroto-Escuela D, Crespo-Ramirez M, Rejon-Orantes J, Palacios-Lagunas D, Martinez-Mata M Cells. 2022; 11(11).

PMID: 35681521 PMC: 9180493. DOI: 10.3390/cells11111826.


Novel insights on the role of spexin as a biomarker of obesity and related cardiometabolic disease.

Kumar S, Mankowski R, Anton S, Babu Balagopal P Int J Obes (Lond). 2021; 45(10):2169-2178.

PMID: 34253845 DOI: 10.1038/s41366-021-00906-2.


Involvement of Neuropeptide Galanin Receptors 2 and 3 in Learning, Memory and Anxiety in Aging Mice.

Locker F, Bieler L, Nowack L, Leitner J, Brunner S, Zaunmair P Molecules. 2021; 26(7).

PMID: 33915732 PMC: 8037218. DOI: 10.3390/molecules26071978.


References
1.
Khoshbouei H, Cecchi M, Dove S, Javors M, Morilak D . Behavioral reactivity to stress: amplification of stress-induced noradrenergic activation elicits a galanin-mediated anxiolytic effect in central amygdala. Pharmacol Biochem Behav. 2002; 71(3):407-17. DOI: 10.1016/s0091-3057(01)00683-9. View

2.
Crawley J . Biological actions of galanin. Regul Pept. 1995; 59(1):1-16. DOI: 10.1016/0167-0115(95)00083-n. View

3.
Branchek T, Smith K, Gerald C, Walker M . Galanin receptor subtypes. Trends Pharmacol Sci. 2000; 21(3):109-17. DOI: 10.1016/s0165-6147(00)01446-2. View

4.
Misane I, Razani H, Wang F, Jansson A, Fuxe K, Ogren S . Modulation of a 5-HT1A receptor-mediated behavioral response by the neuropeptide galanin. Ann N Y Acad Sci. 1999; 863:442-4. DOI: 10.1111/j.1749-6632.1998.tb10719.x. View

5.
Blier P, De Montigny C . Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol Psychiatry. 1998; 44(5):313-23. DOI: 10.1016/s0006-3223(98)00114-0. View